The latest update is out from Aroa Biosurgery Ltd ( (AU:ARX) ).
Aroa Biosurgery Limited announced it will host a webinar to discuss its March Quarterly Results, with CEO Brian Ward and CFO James Agnew leading the session. The webinar, scheduled for April 29, 2025, aims to engage investors and interested parties, offering them an opportunity to submit questions and gain insights into the company’s financial performance. This initiative underscores Aroa’s commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations positively.
More about Aroa Biosurgery Ltd
Aroa Biosurgery is a company specializing in soft-tissue regeneration, developing, manufacturing, and distributing medical and surgical products aimed at improving healing in complex wounds and soft tissue reconstruction. Their products are based on a proprietary AROA ECM™ technology platform, derived from ovine forestomach, and have been used globally in over 7 million procedures. The company, founded in 2008, is headquartered in Auckland, New Zealand, and is listed on the Australian Securities Exchange.
YTD Price Performance: -47.40%
Average Trading Volume: 426,206
Technical Sentiment Signal: Buy
Current Market Cap: A$139.7M
See more data about ARX stock on TipRanks’ Stock Analysis page.